Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Clinical trial NCT02678741 · COMPLETED
Trial details
- NCT number
- NCT02678741
- Sponsor
- Elios Therapeutics, LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2019-10-30
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.